ArticleJACC. Case reports2025
Timely Intervention in Light Chain Cardiac Amyloidosis.
Article in JACC. Case reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundLight-chain cardiac amyloidosis (AL-CA) is often overlooked and misdiagnosed as simple diastolic dysfunction, which can lead to worse outcomes if an accurate diagnosis is delayed. CASE SUMMARY: This case highlights the importance of utilizing a multidisciplinary team approach and multimodality imaging, such as cardiac magnetic resonance and endomyocardial biopsy, in the prompt diagnosis and treatment of AL-CA with a tailored hematologic treatment regimen in a 70-year-old male. Patient achieved complete remission with Dara-CyBorD (daratumumab, cyclophosphamide, bortezomib, and dexamethasone) therapy in 5 months, demonstrating stabilization and potential reversal of myocardial dysfunction. DISCUSSION: Of the many causes of heart failure with preserved ejection fraction, AL-CA can have an especially poor prognosis if diagnosis is delayed. It is crucial to be aware of the clinical presentation of AL-CA, the wide variety of diagnostic tools, multidisciplinary management, and intensive treatment options available, and importance of regular follow-up. TAKE-HOME MESSAGES: Recognizing the hallmark diagnostic features of AL-CA is crucial for differentiating it from other causes of diastolic dysfunction, particularly in the early work-up period. Timely diagnosis of AL-CA and assessment of the infiltrative burden are essential for selecting an individualized hematologic treatment course.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.